Aging Is Becoming a Drug Target. The Question Is Whether It’s a Disease
The Regulatory Revolution

The central obstacle to longevity medicine has always been partly administrative. Regulators need defined indications, measurable outcomes, and evidence that a treatment produces clinically meaningful benefits. Aging, meanwhile, unfolds across decades and affects nearly every organ system.
Recognizing aging as a treatable target would create a new category of medicine. Pharmaceutical companies could develop therapies intended to postpone several diseases simultaneously, potentially changing how clinical trials are designed and how treatments are prescribed. Healthcare systems could begin evaluating interventions according to the healthy years they preserve, rather than waiting for individual diseases to emerge.
The commercial incentives are equally powerful. A drug that meaningfully delays age-related decline could have a market spanning a substantial portion of the adult population. The existing longevity pipeline already demonstrates how established medications can acquire new significance when researchers reinterpret their effects through the biology of aging.
This is why the TAME effort carries consequences beyond metformin. Establishing an accepted way to measure and treat age-related deterioration could unlock an entire field of drug development.